Skip to main content

Short Bowel Syndrome

11
Pipeline Programs
18
Companies
21
Clinical Trials
5 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
2
1
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
563%
Vaccine
338%
+ 16 programs with unclassified modality

On Market (1)

Approved therapies currently available

Takeda
GATTEX KITApproved
teduglutide
Takeda
GLP-2 Analog [EPC]subcutaneous2012

Competitive Landscape

17 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
5 programs
1
Registry for Participants With Short Bowel SyndromeN/A1 trial
TeduglutideN/APeptide1 trial
TeduglutideN/APeptide1 trial
TeduglutidePHASE_3Peptide1 trial
teduglutidePHASE_3Peptide1 trial
Active Trials
NCT01990040Active Not Recruiting1,806Est. Jun 2032
NCT04733066Unknown40Est. Sep 2022
NCT04832087Completed142Est. Aug 2023
+2 more trials
Prevail Therapeutics
1 program
1
Growth HormonePhase 41 trial
Active Trials
NCT00742157Terminated5Est. Oct 2008
Imagine Pharma
Imagine PharmaPA - Pittsburgh
1 program
1
TeduglutidePhase 4Peptide1 trial
Active Trials
NCT03562130Completed25Est. Jul 2020
Biocorp
BiocorpFrance - Issoire
2 programs
1
1
PJ009Phase 31 trial
PJ009Phase 11 trial
Active Trials
NCT06523101Completed24Est. May 2023
NCT06512584Recruiting72Est. Apr 2026
Elgan Pharma
Elgan PharmaIsrael - Nazareth
1 program
1
NTRA-9620Phase 2/31 trial
Active Trials
NCT02865122Terminated2Est. Mar 2018
Hanmi Pharmaceutical
1 program
1
HM15912 ActivePhase 21 trial
Active Trials
NCT04775706Recruiting18Est. May 2028
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Pancreatic EnzymePhase 21 trial
Active Trials
NCT03097029Completed16Est. Feb 2019
NorthSea Therapeutics
NorthSea TherapeuticsNetherlands - Amsterdam
1 program
1
NST 6179Phase 11 trial
Active Trials
NCT05181085Completed70Est. May 2022
MSD
MSDIreland - Ballydine
1 program
1
Oral, live, pentavalent rotavirus vaccine; RotaTeqPhase 1Vaccine1 trial
Active Trials
NCT00767364Completed8Est. Nov 2013
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Oral, live, pentavalent rotavirus vaccine; RotaTeqPhase 1Vaccine
Alcresta Therapeutics
2 programs
RelizorbN/A1 trial
Relizorb Enzyme CartridgeN/A1 trial
Active Trials
NCT03530852Recruiting32Est. Sep 2028
NCT05635747Enrolling By Invitation32Est. Sep 2027
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
2 programs
AmoxicillinPHASE_11 trial
Intralipid 20%PHASE_21 trial
Active Trials
NCT05302531Recruiting10Est. Feb 2025
NCT00793195Unknown24Est. Jan 2012
Regenesis
RegenesisAZ - Scottsdale
1 program
Distraction Enterogenesis in Adult Patients with Short Bowel SyndromeN/A1 trial
Active Trials
NCT05535361Recruiting40Est. Jun 2028
Eclipse Regenesis
Eclipse RegenesisCA - Mountain View
1 program
Distraction Enterogenesis in Adult Patients with Short Bowel SyndromeN/A
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Infant & Toddler Short Gut Feeding Outcomes StudyN/A1 trial
Active Trials
NCT01946503Completed58Est. May 2023
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
guar gumN/A1 trial
Active Trials
NCT00922805Withdrawn0Est. Jan 2012
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Oral, live, pentavalent rotavirus vaccine; RotaTeqPHASE_1Vaccine

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Imagine PharmaTeduglutide
Prevail TherapeuticsGrowth Hormone
BiocorpPJ009
TakedaTeduglutide
Takedateduglutide
Elgan PharmaNTRA-9620
Hanmi PharmaceuticalHM15912 Active
AbbViePancreatic Enzyme
Fresenius KabiIntralipid 20%
BiocorpPJ009
Fresenius KabiAmoxicillin
NorthSea TherapeuticsNST 6179
MSDOral, live, pentavalent rotavirus vaccine; RotaTeq
RegenesisDistraction Enterogenesis in Adult Patients with Short Bowel Syndrome
Alcresta TherapeuticsRelizorb Enzyme Cartridge

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 2,473 patients across 21 trials

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

Start: Jul 2018Est. completion: Jul 202025 patients
Phase 4Completed

Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)

Start: Sep 2003Est. completion: Oct 20085 patients
Phase 4Terminated

Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

Start: Sep 2024Est. completion: Apr 202672 patients
Phase 3Recruiting

Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

Start: Jul 2018Est. completion: Aug 20197 patients
Phase 3Completed

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

Start: Nov 2013Est. completion: Jan 201542 patients
Phase 3Completed

Safety and Efficacy Study in Infant With SBS

Start: Mar 2017Est. completion: Mar 20182 patients
Phase 2/3Terminated

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Start: Mar 2022Est. completion: May 202818 patients
Phase 2Recruiting
NCT03097029AbbViePancreatic Enzyme

Use of Pancreatic Enzymes in Short Bowel Syndrome

Start: Mar 2017Est. completion: Feb 201916 patients
Phase 2Completed

Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?

Start: Jan 2009Est. completion: Jan 201224 patients
Phase 2Unknown

A Study of PJ009 in Healthy Adult Volunteers

Start: Feb 2023Est. completion: May 202324 patients
Phase 1Completed

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

Start: Dec 2022Est. completion: Feb 202510 patients
Phase 1Recruiting

Study of NST-6179 in Healthy Subjects

Start: Nov 2021Est. completion: May 202270 patients
Phase 1Completed
NCT00767364MSDOral, live, pentavalent rotavirus vaccine; RotaTeq

Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome

Start: Jul 2009Est. completion: Nov 20138 patients
Phase 1Completed
NCT05535361RegenesisDistraction Enterogenesis in Adult Patients with Short Bowel Syndrome

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

Start: Sep 2025Est. completion: Jun 202840 patients
N/ARecruiting
NCT05635747Alcresta TherapeuticsRelizorb Enzyme Cartridge

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

Start: Sep 2022Est. completion: Sep 202732 patients
N/AEnrolling By Invitation

Pediatric Teduglutide Registry

Start: May 2021Est. completion: Aug 2023142 patients
N/ACompleted

Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis

Start: Sep 2020Est. completion: Sep 202240 patients
N/AUnknown

A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB

Start: Nov 2018Est. completion: Sep 202832 patients
N/ARecruiting
NCT01990040TakedaRegistry for Participants With Short Bowel Syndrome

Registry for Participants With Short Bowel Syndrome

Start: Jun 2014Est. completion: Jun 20321,806 patients
N/AActive Not Recruiting
NCT01946503Angeles TherapeuticsInfant & Toddler Short Gut Feeding Outcomes Study

Infant & Toddler Short Gut Feeding Outcomes Study

Start: Apr 2013Est. completion: May 202358 patients
N/ACompleted

Fiber Use in Pediatric Short Bowel Syndrome

Start: Jan 2009Est. completion: Jan 20120
N/AWithdrawn

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
5 actively recruiting trials targeting 2,473 patients
18 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.